Fecal Microbiota Transplantation for People Living with Human Immunodeficiency Virus: A Scoping Review
Author(s)
Brenda Caira‐Chuquineyra
Daniel Fernandez‐Guzman
David R. Soriano‐Moreno
Jared Fernandez-Morales
Kevin Flores-Lovon
Sebastian A. Medina-Ramírez
Antony Gonzales-Uribe
Isabel P. Pelayo-Luis
Jose Armando Gonzales Zamora
Jorge Huaringa-Marcelo
Date Issued
22 de abril de 2022
Type
Other
Volume
38
Issue
9
Start Page
700
End Page
708
Abstract
The aim of this scoping review was to determine the characteristics of studies evaluating fecal microbiota transplantation (FMT), as well as its effects and safety as a therapeutic intervention for people living with human immunodeficiency virus (HIV). We conducted a scoping review following the methodology of the Joanna Briggs Institute. We searched the following databases: PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Medline until September 19, 2021. Studies that used FMT in people living with HIV and explored its effects on the health of these people were included. Two randomized and 2 uncontrolled clinical trials with a total of 55 participants were included. Participants were well-controlled HIV-infected people. Regarding microbiota changes, three studies found significant post-FMT increases in Fusobacterium, Prevotella, α-diversity, Chao index, and/or Shannon index, and/or decreases in Bacteroides. Regarding markers of intestinal damage, one study found a decrease in intestinal fatty acid binding protein post-FMT, and another study found an increase in zonulin. Other outcomes evaluated by the studies were as follows: markers of immune and inflammatory activation, markers of immunocompetence (CD4+, and CD8+ T lymphocytes), and HIV viral load; however, none showed significant changes. Clinical outcomes were not evaluated by these studies. Regarding the safety of FMT, only mild adverse events were appreciated. No serious adverse event was reported. The clinical evidence for FMT in people living with HIV is sparse. FMT appears to have good tolerability and, no serious adverse event has been reported so far. Further clinical trials and evaluation of clinically important biomedical outcomes for FMT in people living with HIV are needed.
Subjects